Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
14
|
pubmed:dateCreated |
1996-9-10
|
pubmed:abstractText |
Clinical use of the immunosuppressive drug azathioprine is limited by potentially serious toxic effects related to depression of bone marrow function. The immunosuppressive and toxic properties of azathioprine are regarded as being properties of the cytotoxicity of its metabolite, 6-mercaptopurine (6-MP). However, azathioprine has an immunosuppressive effect additional to that attributable to 6-MP alone, and we propose that this is associated with an action of the methylnitroimidazolyl substituent. This suggests a route to the rational design of nontoxic immunosuppressants by replacing the 6-MP component of azathioprine with nontoxic thiols. We have synthesized and tested in vitro 24 such analogues, with two being further tested in vivo. In the human mixed lymphocyte reaction, virtually all compounds showed some degree of activity, 10 compounds being more active than azathioprine. In vivo, two compounds were more effective than azathioprine at prolonging graft survival in mice. In an oral toxicity study in male CD1 mice at doses equivalent to those at which azathioprine caused severe bone marrow depression both analogues had no toxic effects. Our results show that the immunosuppressive effects and bone marrow toxicity of azathioprine are not a consequence of release of 6-MP alone, and with appropriate modification can be separated, an approach which may lead to less toxic immunosuppressive drugs.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
0022-2623
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
5
|
pubmed:volume |
39
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2690-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8709098-6-Mercaptopurine,
pubmed-meshheading:8709098-Animals,
pubmed-meshheading:8709098-Azathioprine,
pubmed-meshheading:8709098-Cells, Cultured,
pubmed-meshheading:8709098-Drug Design,
pubmed-meshheading:8709098-Humans,
pubmed-meshheading:8709098-Immunosuppressive Agents,
pubmed-meshheading:8709098-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:8709098-Male,
pubmed-meshheading:8709098-Mice,
pubmed-meshheading:8709098-Skin Transplantation,
pubmed-meshheading:8709098-Structure-Activity Relationship
|
pubmed:year |
1996
|
pubmed:articleTitle |
Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects.
|
pubmed:affiliation |
University Department of Medicine, Royal Hallamshire Hospital, Sheffield, U.K.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|